Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

Use of the SpiderMass for in Vivo Analysis of the Skin in Five Chronic Inflammatory Dermatosis

Lead Sponsor:

Pierre Fabre Dermo Cosmetique

Conditions:

Acne

Atopic Dermatitis

Eligibility:

All Genders

18-55 years

Phase:

NA

Brief Summary

The physiological states of the skin are characterized by a certain homeostasis linked to the balance of the metabolic pathways. When these pathways are deregulated, the proteic, lipidic and metabolic...

Eligibility Criteria

Inclusion

  • -\> INCLUSION CRITERIA
  • CRITERIA RELATED TO THE POPULATION:
  • Male or female subject having signed a written informed consent for his/her participation to the study
  • Subject with a phototype II to IV according to the Fitzpatrick scale
  • Subject affiliated to a social security system or health insurance, or is a beneficiary
  • For woman of childbearing potential use of an effective method of contraception, as assessed by the investigator for at least 4 weeks before inclusion in the study
  • For acne of the face subgroup and its associated control: Male or female, 18 to 30 years old included
  • For atopic dermatitis of the upper limb subgroup and its associated control: Male or female, 20 to 50 years old included
  • For vulgar plaque psoriasis subgroup and its associated control: Male or female, 20 to 55 years old included
  • For telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: Male or female, 30 to 55 years old included
  • For seborrheic dermatitis of scalp subgroup and its associated control: Male or female, 20 to 45 years old included
  • CRITERIA RELATED TO DERMATOSIS:
  • For subjects of the acne of the face subgroup :
  • Subjects with mild to severe acne on the face with a GEA (Global Acne Evaluation) score of 2 to 4 on a rating scale ranging from 0 (no injury) to 5 (very severe)
  • Subject presenting on the face, at least one zone:
  • Lesional in immediate border of a papule
  • Peri-lesional near inflammatory lesions (papule, about 1 cm)
  • Subject presenting on the inner side of the forearm a reference zone without lesion
  • For subjects in the atopic dermatitis subgroup of upper limbs:
  • Subject with atopic dermatitis on the upper limbs, mild to moderate with SCORAD (SCORing Atopic Dermatitis) between 15 and 40 included with:
  • •A dryness score ≥ 2 on a scale ranging from 0 (absent) to 3 (severe)
  • Subject having at least one inflammatory flare of atopic dermatitis on the upper limbs in the 2 years before the day of inclusion
  • Subject presenting on the upper limb (hand excluded) at least one zone:
  • •Lesional defined by the signs of target SCORAD between 3 and 12:
  • • Erythema from 1 to 3
  • • Dryness ≥2
  • • Oedema / papule from 0 to 3
  • Lesions oozing or crusting 0
  • Excoriation of 0
  • Lichenification from 0 to 3 On a scale ranging from 0 (absent) to 3 (severe)
  • Peri-lesional near the lesion zone (about 1cm)
  • Subject presenting on the inner side of the forearm a reference zone without lesion
  • For vulgar plaque psoriasis subgroup
  • Subject with mild to moderate erythematous-squamous plaque psoriasis whose IGA (Investigator Global Assessment) score is between 2 and 3, on a rating scale ranging from 0 (clear) to 5 (very severe)
  • Subject with on the upper limb (hand excluded) or lower limb at least one zone:
  • Lesional:
  • Without fissure and without crust
  • With erythema score ≥ 1 on a scale ranging from 0 (absent) to 3 (severe)
  • With desquamation score between 1 (mild) and 2 (moderate) on a scale ranging from 0 (absent) to 3 (severe)
  • With an oedema score of 0 (absent) on a scale ranging from 0 (absent) to 3 (severe)
  • Peri-lesional:
  • Without fissure and without crust
  • Near the lesion zone (about 1 cm)
  • Subject presenting on the inner side of the forearm a reference zone without lesion
  • For telangiectasic erythrocouperosis papule of the face (rosacea) subgroup
  • \- Subject with telangiectasic erythrocouperosis and papule of the face mild to moderate with an IGA score between 2 and 3 on a rating scale ranging from 0 (absent) to 4 (severe)
  • Subject presenting on the face at least one zone:
  • • Lesional: immediate border of the papule with a persistent erythema score ≥ 1 on a rating scale ranging from 0 (absent) to 3 (severe)
  • • Peri-lesional:
  • • Near inflammatory lesions (papule, about 1 cm)
  • • Ranging of at least 1 point less in the erythema score compared to the lesion zone
  • Subject presenting on the inner side of the forearm a reference zone without lesion
  • For seborrheic dermatitis of scalp subgroup :
  • Subject with mild to moderate seborrheic dermatitis with an IGA score between 2 and 3 on a rating scale ranging from 0 (absent) to 4 (severe)
  • Subject presenting on the scalp at least one zone:
  • Lesional:
  • with erythema score ≥ 1 on a scale of 0 (absent) to 3 (severe)
  • with clinically visible scales
  • Peri-lesional:Near the lesion zone (about 1 cm)
  • Subject presenting on the inner side of the forearm a reference zone without lesion
  • NON INCLUSION CRITERIA
  • CRITERIA RELATED TO THE POPULATION:
  • For woman of childbearing potential: pregnant or breastfeeding
  • Subject unable to understand the information given including study procedures (for linguistic or psychiatric reasons) and to give his/her consent in writing
  • Subject who, in the judgement of the investigator, is not likely to be compliant with study-related constraints and requirements
  • Subject who has forfeited his/her freedom by administrative or legal award or is under guardianship
  • Subject who is in a position likely to represent a conflict of interest and/or is a family member of any people involved in the conduct of the study (secretary, nurse, technician…) of the investigational site
  • Subject who is currently participating, who plans to participate or who has participated in another clinical study liable to interfere with the study assessments according to the investigator's assessment
  • CRITERIA RELATED TO DERMATOSIS AND CUTANEOUS CONDITION:
  • Subject with premature cutaneous aging linked to a genetic disease
  • Subject with solar erythema in at least one zone under study
  • Subject with a tattoo, scar or other dermatological sign on at least one study zone that may interfere with the study according to the investigator's assessment
  • Subject with autoimmune disease
  • Subject with any type of complication on at least one study area (excoriation type, primary, viral, fungal or parasitic bacterial infection, etc.) according to the investigator's assessment
  • Criteria for control subgroups:
  • \- Subject with a dermatosis or any type of lesion on the zone corresponding to the lesional, peri-lesional zone or reference zone of the associated subgroup dermatosis likely to interfere with the study according to the investigator's assessment
  • Criteria for chronic inflammatory dermatitis:
  • For subjects of the acne of the face subgroup:
  • \- Subject with another dermatosis (chronic / acute, inflammatory, infectious, immune) on the face that could interfere with the study according to the investigator's assessment
  • For subjects in the atopic dermatitis subgroup of upper limbs:
  • \- Subject with another dermatosis (chronic / acute, inflammatory, infectious, immune) on the upper limb (s) to the study likely to interfere with the study according to the investigator's assessment
  • For vulgar plaque psoriasis subgroup
  • Subject with an isolated palmo-plantar form of psoriasis
  • Subject with an isolated form of cutaneous psoriasis other than in plaque (in gout, pustular, erythrodermic or inverted elbow creases (psoriasis of the mucous membranes))
  • Subject with another dermatosis (chronic / acute, inflammatory, infectious, immune) on the upper limb (s) and/or lower limb(s) to the study likely to interfere with the study according to the investigator's assessment
  • For telangiectasic erythrocouperosis papule of the face (rosacea) subgroup
  • \- Subject with another dermatosis (chronic / acute, inflammatory, infectious, immune) on the face that could interfere with the study according to the investigator's assessment
  • For seborrheic dermatitis of scalp subgroup :
  • Seborrheic dermatitis under medical treatment
  • Subject with another dermatosis (chronic / acute, inflammatory, infectious, immune) on the scalp likely to interfere with the study according to the investigator's assessment (in particular contact eczema or alopecia)
  • CRITERIA RELATED TO TREATMENTS AND PRODUCTS
  • For all subjects :
  • Oral intake of isotretinoin or acitretin (oral vit-A and derivatives) within the 6 months prior to the inclusion visit or the day of the visit
  • Local retinoid treatment on at least one study zone, which may interfere with the results of the study according to the investigator's assessment within the month preceding the inclusion visit or the day of the visit
  • Phototherapy treatment in at least one study zone within 4 weeks prior to the inclusion visit or the day of the visit
  • Topical or oral treatment established or modified during the previous weeks or to be established or modified during the study, which may interfere with the results of the study according to the investigator's assessment ( for example modifying the cutaneous characteristics: treatment inducing pigmentation), keratolysis, ...)
  • Anti-inflammatory treatment (steroidal or nonsteroidal) taken daily and repeatedly for more than 5 consecutive days during the week preceding the inclusion visit
  • Application of any topical vitamin D-derived treatment on at least one study zone within 3 weeks prior to the inclusion visit or the day of the visit
  • Application of dermocorticoid topical or immunomodulatory topical treatments (tacrolimus), antifungals, local antibiotics on at least one study zone in the 3 weeks prior to the inclusion visit or the day of the visit
  • Application of water, product or topical treatment on at least one zone under study after the last wash the day before the visit
  • Application of water, topical product or make-up on at least one zone the day of the inclusion visit
  • For seborrheic dermatitis of scalp subgroup and its associated control :
  • Use on the scalp of any product that can be active on squamous conditions, rinsed or posed (anti-dandruff, anti-fungal shampoo, vinegar rinse, essential oils ...) within 2 weeks prior to the inclusion visit or the day of the visit
  • Any technique to change the color or condition of the hair (coloring, discoloration, permanent, smoothing / straightening, ..) performed within 2 weeks prior to the inclusion visit or the day of the visit
  • Washing of the scalp done within 2 days before the inclusion visit or the day of the visit

Exclusion

    Key Trial Info

    Start Date :

    December 13 2019

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    February 2 2024

    Estimated Enrollment :

    210 Patients enrolled

    Trial Details

    Trial ID

    NCT04472546

    Start Date

    December 13 2019

    End Date

    February 2 2024

    Last Update

    June 7 2024

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Centre de Recherche sur la Peau

    Toulouse, France, 31400